Orionis Biosciences enters molecular glue deal with Genentech

Privately-held genome-scale drug discovery company Orionis Biosciences today revealed a multi-year collaboration with Genentech, the US biotech subsidiary of Swiss pharm giant Roche (ROG: SIX), to discover novel small molecule medicines for challenging targets in major disease areas, including oncology and neurodegeneration.

Orionis’ Allo-Glue platform utilizes multiple unique approaches to discover drug-like small molecules against disease targets that have remained elusive to traditional discovery approaches.

The accord provides for Orionis to be responsible for the discovery and optimization of molecular glues for Genentech’s designated targets, while Genentech will be responsible for subsequent later-stage pre-clinical, clinical development, regulatory filing, and commercialization of such small molecules.